Chin up, Kythera gets ATX-101 back from Bayer
This article was originally published in Scrip
Executive Summary
Kythera Biopharmaceuticals spun Bayer's decision to offload the double chin drug ATX-101 as a positive change for the Calabasas, California-based company, which paid $33m in stock to reacquire global rights to the injectable aesthetic therapy.